MyFinsight
Home
Blog
About
Proceeds from registered
direct offering of...
$11,397,459
Proceeds from the
exercise of prefunded...
$132
Net cash provided by
financing activities
$11,291,325
Canceled cashflow
$106,266
Net increase in cash
$6,704,138
Canceled cashflow
$4,587,187
Payment of issuance
costs
$106,266
Share-based compensation
expense
$449,419
Decrease in prepaid
expenses and other...
-$288,886
Increase (decrease) in
accrued expenses and...
$187,830
Deferred sublease income
-$38,911
Reduction in carrying
amount of right-of-use...
$16,839
Loss on foreign
exchange
-$5,860
Deferred tax expense
$1,193
Net cash used in
operating activities
-$4,587,187
Canceled cashflow
$988,938
Net loss
-$4,986,614
Decrease in accounts
payable
-$589,511
Back
Back
Cash Flow
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)
source: myfinsight.com